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Protein kinase D1 (PKD1) is involved in cellular processes including protein secretion, proliferation and apoptosis. Studies suggest PKD1 is
activated by various stimulants including gastrointestinal (GI) hormones/neurotransmitters and growth factors in a protein kinase C (PKC)-dependent
pathway. However, little is known about the mechanisms of PKD1 activation in physiologic GI tissues. We explored PKD1 activation by GI
hormones/neurotransmitters and growth factors and the mediators involved in rat pancreatic acini. Only hormones/neurotransmitters activating
phospholipase C caused PKD1 phosphorylation (S916, S744/748). CCK activated PKD1 and caused a time- and dose-dependant increase in serine
phosphorylation by activation of high- and low-affinity CCKA receptor states. Inhibition of CCK-stimulated increases in phospholipase C, PKC
activity or intracellular calcium decreased PKD1 S916 phosphorylation by 56%, 62% and 96%, respectively. PKC inhibitors GF109203X/Go6976/
Go6983/PKC-ζ pseudosubstrate caused a 62/43/49/0% inhibition of PKD1 S916 phosphorylation and an 87/13/82/0% inhibition of PKD1 S744/748
phosphorylation. Expression of dominant negative PKC-δ, but not PKC-ε, or treatment with PKC-δ translocation inhibitor caused marked inhibition
of PKD phosphorylation. Inhibition of Src/PI3K/MAPK/tyrosine phosphorylation had no effect. In unstimulated cells, PKD1 was mostly located in
the cytoplasm. CCK stimulated translocation of total and phosphorylated PKD1 to the membrane. These results demonstrate that CCKA receptor
activation leads to PKD activation by signaling through PKC-dependent and PKC-independent pathways.
© 2006 Elsevier B.V. All rights reserved.Keywords: PKD1 activation; Pancreas; Cholecystokinin; Gastrointestinal hormone; Growth factor; PKC1. Introduction
Protein kinase D1 (PKD1), PKD2 and PKD3 constitute the
recently identified PKD family, a subclass of the AGC family of
serine/threonine kinases, with structural and enzymological
properties different from those of members of the PKC family
[1,2]. PKD1 is composed of different domains: a N-terminal
region, two cysteine-rich zinc-finger regions, a region rich in
negatively charged amino acids, a pleckstrin-homology domain
and a Ser/Thr kinase catalytic domain (for review, see [3]). PKD1
can be activated by growth factors, oxidative stress, thrombin,⁎ Corresponding author. Tel.: +1 301 496 4201; fax: +301 402 0600.
E-mail address: robertj@bdg10.niddk.nih.gov (R.T. Jensen).
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doi:10.1016/j.bbamcr.2006.12.008bioactive lipids, cross-linking of B- and T-cell receptors and
some G-protein coupled receptors (GPCR) [4–7]. For most of
these stimuli, direct phosphorylation by a member of the PKC
family is reported to be themajormechanism of PKD1 activation
in vivo [8]. This transphosphorylation occurs at the serine
residues 744/748 in the activation loop of the kinase domain [8].
Mutational studies have shown that phosphorylation of these
residues is required and sufficient for PKC-mediated PKD1
activation by a number of stimulants [9]. A second important
phosphorylation event in PKD1 activation concerns serine 916
in the C-terminal region. This residue is autophosphorylated by
activated PKD1, leading to a change in conformation that
stabilizes PKD1 in an active state and influences duration of
kinase activation [10]. Phosphorylation of S916 has been shown
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resting cells, PKD1 is located mainly in the cytoplasm, upon
stimulation, PKD1 migrates to the membrane where it is
activated [12–14]. Activation of PKD1 leads to regulation of
multiple cellular functions including Golgi organization and
protein secretion [15], cell proliferation [16], invasion [17] and
regulation of apoptosis [18].
Although PKD1 has been extensively studied in multiple
cellular systems, several aspects of GPCR-mediated PKD1
activation remain controversial or not determined, including
the role of changes in intracellular calcium levels in media-
ting PKD1 activation, the existence and relevance of PKC-
independent pathways of PKD1 activation by GPCRs, the PKC
isoforms or intracellular mediators other than PKC involved in
PKD1 activation by CCK and the changes in the intracellular
distribution of PKD1 upon activation. Furthermore, compara-
tive data on kinetic and stoichiometric variables and intracel-
lular distribution of the two phosphorylated PKD1 forms (S916
and S744/748) are lacking and only very limited information is
available on PKD1 activation in native GI cells or tissues and
the intracellular signaling cascades involved.
Intracellular signaling mechanisms for gastrointestinal (GI)
growth factors as well as GI hormones/neurotransmitters have
been extensively studied in dispersed pancreatic acini because
these cells are highly responsive to various stimuli [19]. A
number of GI hormones/neurotransmitters and growth factors
that are known to alter pancreatic acinar cell function have been
reported to activate PKD1 in other cells [20–22]. As PKD1
may play a central role in the regulation of protein trafficking,
cell proliferation and induction of apoptosis in other cell
systems [15–18], an understanding of the involvement of
PKD1 in the signaling cascades of these GI hormones/
neurotransmitters or growth factors in pancreatic tissue is
important, because many of these stimuli play an important role
in pancreatic disease. Therefore, to address the issues on PKD1
activation detailed above, we have analyzed the role of GI
hormones/neurotransmitters and growth factors in PKD1
activation in pancreatic acinar cells and the intracellular
signaling cascades involved.
2. Materials and methods
2.1. Materials
Male Sprague–Dawley rats (150–250 g) were obtained from the Small
Animals Section, Veterinary Resources Branch, National Institutes of Health
(NIH), Bethesda, MD. Rabbit anti-phospho-PKD1-pS916, rabbit anti-phospho-
PKD1-pS744/748, rabbit anti-PKD antibodies, rabbit anti-phospho-Src family
(Y416), mouse anti-phospho p44/42 MAPK (T202/Y204) and mouse anti-
phospho Akt (S473) were purchased from Cell Signaling Technology, Inc.
(Beverly, MA). Rabbit anti-PKD (C20), rabbit anti-PKD1 (N20), bovine anti-goat
horseradish peroxidase (HRP)-conjugate and anti-rabbit-HRP-conjugate antibo-
dies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-E-
Cadherin, anti PKC-delta and anti PKC-epsilon were purchased from BD
Biosciences (San Jose, CA). Anti-Calpain was from BioSource International, Inc.
(Camarillo, CA). Rabbit anti-PKD2 was from Bethyl Laboratories (Montgomery,
TX). Tris/HCl pH 8.0 and 7.5 were form Mediatech, Inc. (Herndon, VA). 2-
mercaptoethanol, protein assay solution and SDSwere fromBio-Rad Laboratories
(Hercules, CA). CaCl2 and MgCl2 were from Quality Biological, Inc.
(Gaithersburg, MD). Dulbecco's phosphate buffered saline (DPBS), glutamine(200mM), Tris/glycine/SDS buffer (10×), and Tris/glycine buffer (10×) were from
Biosource. Minimal essential media (MEM) vitamin solution, basal medium Eagle
(BME) amino acids 100× and Tris-Glycine gels were from Invitrogen (Carlsbad,
CA). COOH-terminal octapeptide of cholecystokinin (CCK-8), hepatocyte growth
factor (HGF), bombesin, insulin-like growth factor 1 (IGF-I), basic fibroblast
growth factor (bFGF), vasoactive intestinal peptide (VIP), endothelin and secretin
were from Bachem Bioscience Inc. (King of Prussia, PA). EGF, thapsigargin,
PDGF, GF109203X, A23187, LY294002, Go6976, Go6983, PKCζ pseudosub-
strate inhibitor, wortmannin, PD98059, U0126, AG527 (B44), PP2, PP3, syntide-
2, U-74321, U-74343 and deoxycholic acid were fromCalbiochem (La Jolla, CA).
Carbachol, insulin, TGF-β1, dimethyl sulfoxide (DMSO), 12-O-tetradecanoyl-
phorbol-13-acetate (TPA), L-glutamic acid, fumaric acid, pyruvic acid, trypsin
inhibitor, HEPES, Triton-X, TWEEN®, phenylmethanesulfonylfluoride (PMSF),
EGTA, sucrose, sodium-orthovanadate and sodium azide were from Sigma-
Aldrich, Inc. (St. Louis, MO). Albumin standard, Protein G beads, Super Signal
West (Pico, Dura) chemiluminescent substrate and stripping buffer were from
Pierce (Rockford, IL). Protease inhibitor tablets were from Roche (Basel,
Switzerland). Purified collagenase (type CLSPA) was from Worthington
Biochemicals (Freehold, NJ). ATP and γ32P-ATP were from Amersham (Piscat-
away, NJ). P81 phosphocellulose paper was from Upstate (Charlottesville, VA).
Nitrocellulose membranes were from Schleicher and Schuell BioSience, Inc.
(Keene, NH). Alexa 594-conjugated anti-rabbit secondary antibody was from
Molecular Probes (Eugene, OR). Poly-L-lysine coated slides and sample chambers
were fromWescor (Logan, UT). Ad5-CMV-PKC-delta-DN and Ad5-CMV-PKC-
epsilon-DN were from Seven Hill Bioreagents (Cincinnati, OH), Ad5-CMV-GFP
and Ad5-CMV were from QBiogene (Montreal, Canada).
2.2. Methods
2.2.1. Tissue Preparation
Pancreatic acini were obtained by collagenase digestion as previously
described [23]. Standard incubation solution contained 25.5 mM HEPES (pH
7.45), 98 mM NaCl, 6 mM KCl, 2.5 mM NaH2PO4, 5 mM sodium pyruvate,
5 mM sodium glutamate, 5 mM sodium fumarate, 11.5 mM glucose, 0.5 mM
CaCl2, 1 mM MgCl2, 1 mM glutamine, 1% (w/v) albumin, 0.01% (w/v) trypsin
inhibitor, 1% (v/v) vitamin mixture and 1% (v/v) amino acid mixture.
2.2.2. Acini stimulation
After collagenase digestion, dispersed acini were pre-incubated in standard
incubation solution for 2 h at 37 °C with or without inhibitors as described
previously [23]. After pre-incubation 1 ml aliquots of dispersed acini were
incubated at 37 °C with or without stimulants. Cells were lysed in lysis buffer
(50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate,
0.1% sodium azide, 1 mM EGTA, 0.4 mM EDTA, 0.2 mM sodium
orthovanadate, 1 mM PMSF, and one protease inhibitor tablet per 10 ml).
After sonication, lysates were centrifuged at 10,000×g for 15 min at 4 °C and
protein concentration was measured using the Bio-Rad protein assay reagent.
Equal amounts of samples were analyzed by SDS-PAGE and Western blotting.
2.2.3. Subcellular Fractionation
After stimulation acini were resuspended in membrane lysis buffer (50 mM
Tris/HCl pH7.5, 150mMNaCl, 0.1% sodium azide, 1mMEGTA, 0.4mMEDTA,
0.2 mM sodium orthovanadate, 1 mM PMSF, and one protease inhibitor tablet per
10 ml). After homogenization for 30 s (Polytron homogenizer, Brinkmann
Instruments) lysates were centrifuged at 500×g for 15 min to separate nuclei, debri
and fat. The supernatant (cytosol and membrane fraction) was centrifuged for
30min at 4 °C and 60,000×g to separate cytosol andmembrane fraction. The pellet
containing the membrane fraction was washed twice in membrane lysis buffer,
resuspended in lysis buffer (with detergents as described above), sonicated for 3 s
and then centrifuged at 10,000×g for 15 min at 4 °C. Protein concentration was
measured using Bio-Rad protein assay reagents and equal amounts of protein were
subjected to SDS-PAGE and analyzed by Western blotting.
2.2.4. Western blotting
Whole cell lysates, immunoprecipitates or lysates of subcellular fractions
were subjected to SDS-PAGE using 10% and 4–20% Tris-glycine gels. After
electrophoresis, protein was transferred to nitrocellulose membranes. Mem-
branes were blocked in blocking buffer (50 mM Tris/HCl pH 8.0, 2 mM CaCl2,
Fig. 1. PKDs and their phosphorylated forms occur in rat pancreatic acini. Rat
pancreatic acini were treated for 5 min with 10 nMCCK and then lysed. Western
blots were analyzed using either anti-PKD1 antibody (Ab) (lane 1), anti-pS744/
748 PKD1 Ab (lane 2), anti-pS916 PKD1 Ab (lane 3) or anti PKD2 Ab (lane 4).
Bands were visualized using chemiluminescence. Positions of molecular mass
markers are shown on the left. The position of PKD1 and PKD2 is indicated with
arrows. Results are representative of 2 other experiments.
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room temperature for 1 h. Membranes were then incubated with primary
antibody. Membranes were incubated with HRP-conjugated secondary antibody
(anti-mouse, anti-rabbit, anti-goat) for 45 min. Membranes were then washed
twice in blocking buffer and twice in washing buffer (50 mM Tris/HCl pH 8.0,
2 mM CaCl2, 80 mM NaCl, 0.05% Tween® 20), incubated with chemilumines-
cence detection reagents and finally exposed to Kodak Biomax film (XAR,
MR). The intensity of the protein bands was measured using Kodak ID Image
Analysis. For re-probing, membranes were incubated in Stripping buffer for
30 min at room temperature, washed in washing buffer, blocked for 1 h in
blocking buffer and re-probed as described above.
2.2.5. Immunoprecipitation and PKD1 kinase assay
After treatment with or without 10 nMCCK for 5min as indicated, pancreatic
acini were lysed (50 mM Tris-HCl pH 7.5, 1% Triton–X, 2 mM EGTA, 2 mM
EDTA, 2 mMDTT), lysates were sonicated, cleared by centrifugation at 10,000×
g for 15 min at 4 °C and protein concentration was measured using the Bio-Rad
protein assay reagent. 1800 μg of protein were incubated with a PKD antibody
for 2 h (C-20 from Santa-Cruz, diluted 1:100), conjugates were immunopreci-
pitated using protein G coupled to agarose beads and immunoprecipitates were
washed twice in lysis buffer and twice in kinase buffer (30 mMTris–HCl pH 7.5,
10 mM MgCl2, 2 mM DTT). For assessment of PKD1 autophosphorylation,
10 μl of kinase buffer containing 2.5 μCi 32P-ATP/sample (diluted with cold ATP
to give a final concentration of 100 μM) was added to 20 μl of beads. Samples
were incubated at 30 °C for 10 min and the reaction was stopped by addition of
1 ml of ice-cold kinase buffer. Immunoprecipitates were recovered and an equal
amount of 2× running buffer was added. Samples were submitted to SDS-PAGE
and gels were dried prior to autoradiography. To determine phosphorylation of
the synthetic substrate syntide-2, immunoprecipitates (20 μl) were incubated
with 30 μl of kinase buffer containing 2 μCi/sample 32P-ATP (diluted with cold
ATP to give a final concentration of 100 μM) and 5 μg/μl syntide-2 for 10 min at
30 °C. Reactions were terminated by addition of 100 μl phosphoric acid (0.75%)
and 75 μl of the supernatant was spotted onto P81 phosphocellulose squares.
These were washed thoroughly 5 times 5 min in 0.75% phosphoric acid and then
5 min in acetone. Squares were allowed to dry and incorporation of 32P into
syntide-2 was assessed by Cerenkov counting.
2.2.6. Immunocytochemistry and immunofluorescence imaging
After treating pancreatic acini with or without stimulants as indicated, cells
were fixed, transferred to glass slides and blocked as previously reported [24].
Slides were incubated with an anti-PKD antibody (C-20, Santa Cruz) at a
dilution of 1:500 and an anti-E-cadherin antibody (1:100) overnight at 4 °C.
Reactivity was demonstrated by incubation with Alexa Fluor555-conjugated
goat anti-rabbit and Alexa Fluor468-conjugated goat anti mouse secondary
antibodies at a dilution of 1:500 for 2 h at room temperature. Negative controls
consisted of replacement of primary antibody with an isotype-matched control.
Slides were analyzed as previously reported [24].
2.2.7. Pancreatic acinar isolation, infection and culture
Pancreatic acini were isolated as described above, infected with adenovirus
at various titers and cultured on dishes coated with rat tail collagen in
Waymouth's medium containing 0.5% FBS, 100 U/ml penicillin, 100 μg/ml
streptomycin and 0.2 mg/ml soybean trypsin inhibitor as described previously
[25]. After 24 h, stimulants were added and cells lysed as described above.
2.2.8. Statistical analysis
All experiments were performed at least 4 times. Data are presented as mean±
SEM and were analyzed using the Student's t-test for paired data using the
software StatView (SAS Institute, Casy, NC). P values <0.05 were considered
significant.
3. Results
3.1. PKD1 is expressed and phosphorylated by CCK in rat
pancreatic acini
We first determined whether PKD1 was present in pancreatic
acinar cells and whether it was phosphorylated in response tostimulation by CCK, a major physiological stimulant of these
cells [26]. Using a specific PKD1 antibody for Western blotting
on whole cell lysates from rat pancreatic acini treated with
10 nM CCK for 5 min, a single 115 kDa protein was detected
(Fig. 1, lane 1), whereas a single 105 kDa protein was present
when a specific PKD2 antibody was used (Fig. 1, lane 4),
demonstrating the presence of both PKD1 and PKD2. When
these lysates were submitted to Western blotting with specific
antibodies directed against PKD1 phosphorylated at S916 and
S744/748, proteins co-migrating with PKD1, but not PKD2,
were visualized (Fig. 1, lanes 2 and 3), showing the presence of
both forms of phosphorylated PKD1 in pancreatic acini treated
with CCK. These findings demonstrate that PKD1 and PKD2
are present in rat pancreatic acini and that PKD1 is
phosphorylated at S916 and S744/748 in response to CCK.
3.2. PKD1 is phosphorylated on S916 and S744/748 by CCK,
carbachol and bombesin, but not by growth factors in rat
pancreatic acini
Numerous GI growth factors as well as GI hormones/
neuropeptides activate pancreatic acinar cells [19]. To assess
whether stimulation by GI hormones or growth factors can
cause phosphorylation of PKD1, we analyzed the alterations in
the phosphorylation of S916 (a PKD1 autophosphorylation site
reflecting activation) and S744/748 (a site for transphosphory-
lation by PKC isoforms) in whole cell lysates from rat pan-
creatic acini treated with various stimuli (Fig. 2). Phosphory-
Fig. 2. Ability of various pancreatic secretagogues and growth factors to stimulate PKD1 S916 and S744/748 phosphorylation in rat pancreatic acini. Top: rat
pancreatic acini were treated with no additions or with 10 nM CCK, 10 μM carbachol, 10 nM bombesin, 100 nM secretin or 100 nM VIP for 5 min, with 100 nM
endothelin for 10 min, or with 1 mM 8-Br-cAMP for 30 min. Upper 3 panels: membranes were analyzed using either anti-pS916 PKD1 Ab (panel 1) or anti-pS744/748
PKD1 Ab (panel 2). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 3). Lower 2 panels: For positive
controls for stimulation by pancreatic secretagogues, membranes were analyzed using anti-phospho Akt and anti-phospho MAPK Ab (panels 4, 5). The bands were
visualized using chemiluminescence. Results from a representative experiment of 6 experiments are shown. Bottom: rat pancreatic acini were treated with no additions,
with 10 nM CCK for 5 min as positive control or with 10 nM EGF for 2.5 min, with 1 μM insulin or 100 mg/ml PDGF for 5 min, with 100 ng/ml bFGF or 1 nM HGF
for 10 min, with 3 nMVEGF or 100 nM IGF1 for 15 min or with 1 nM TGFβ for 60 min. Upper 3 panels: membranes were analyzed using either anti-pS916 PKD1 Ab
(panel 1) or anti-pS744/748 PKD Ab (panel 2). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 3).
Lower panel: for positive controls for stimulation by growth factors, membranes were analyzed using anti-phospho Akt Ab (panel 4). The bands were visualized using
chemiluminescence. Results from a representative experiment of 4 experiments are shown.
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increased after treatment with GI hormones causing mobiliza-
tion of intracellular calcium and PKC activation (i.e. CCK,
carbachol, bombesin) (Fig. 2, top panel, lanes 2–4) [19], but not
after treatment with GI hormones that increase cellular cyclic
AMP and cause PKA activation (i.e. secretin, VIP) (Fig. 2, top
panel, lanes 5–8) [19] or treatment with various pancreatic
growth factors (Fig. 2, bottom panel). To confirm that each
stimulus tested can alter acinar cell function, we showed that
each GI hormone stimulated an increase in phosphorylation of
MAPK or Akt (Fig. 2) and that each growth factor stimulated an
increase in Akt phosphorylation (Fig. 2), indicating that each
stimulus had an effect on acinar cells in our assay.
3.3. PKD1 is activated by CCK in rat pancreatic acini
We next wanted to determine if CCK not only causes PKD1
phosphorylation, but also activation. In-vitro kinase assaysmonitoring PKD autophosphorylation and phosphorylation of
the synthetic substrate syntide-2 by PKD have been used in other
experimental models to determine PKD activation by a given
stimulus [5,27]. Incubation with 10 nMCCK for 5 min caused an
8.6±0.5-fold increase in PKD1 autophosphorylation (Fig. 3,
upper panel) and a highly significant (p<0.001) increase in
phosphorylation of the synthetic substrate syntide-2 (Fig. 3, lower
panel), demonstrating activation of PKD kinase activity by CCK.
3.4. Time-dependence and dose-dependence of PKD1
phosphorylation by CCK
Phosphorylation of both S916 and S744/748 of PKD1
rapidly increased after CCK stimulation with a detectable effect
after 30 s and a maximal effect after 10–15 min of stimulation,
lasting over 60 min (Fig. 4). The increase in S916 phosphoryla-
tion occurred significantly faster (p<0.05) than the increase in
S744/748 phosphorylation (Table 1). The dose–response of
Fig. 3. CCK activates PKD1 in rat pancreatic acini. Rat pancreatic acini were
treated for 5 min with 10 nM CCK or with no additions and then lysed. For
determination of PKD1 autophosphorylation, immunoprecipitates were incu-
bated with kinase buffer containing 32P-ATP and subjected to electrophoresis.
Gels were dried and subjected to autoradiography (upper panel). Shown is a
representative experiment of 3 others. For assessment of phosphorylation of the
exogenous substrate syntide-2, immunoprecipitates were incubated with kinase
buffer containing 32P-ATP and syntide-2. The reaction was stopped by adding
0.75% phosphoric acid and spotted onto P81 phosphocellulose squares.
Incorporation of 32P was determined by scintillation counting. The values
indicated are the means±S.E. of 7 independent experiments and are expressed as
percent of the pretreatment value.
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comparable for both phosphorylation sites (Fig. 5). Increase in
phosphorylation was detectable at concentrations greater than
0.01 nM CCK and reached a maximum at 10 nM CCK (Fig. 5).
Further increasing the CCK concentration to 100 or 1000 nM
CCK did not increase the level of PKD1 S916 or S744/748
phosphorylation (Fig. 5). With maximal CCK stimulation, the
fold increase over basal phosphorylation levels was signifi-
cantly greater (p=0.013) for S916 than for S744/748PKD1
(Table 1).
3.5. CCK-induced PKD1 serine phosphorylation is mediated
both by the high- and the low-affinity CCKA receptor
The CCKA receptor on pancreatic acini can exist in both a
high and low affinity receptor state [19,26]. To analyze the
possible role of each receptor state in causing CCK mediated
PKD1 phosphorylation, we analyzed the effect of CCK-JMV, a
CCK synthetic analog which in rat pancreatic acini functions as
an agonist of the high-affinity CCKA state and as an antagonistat the low-affinity CCKA receptor state [28,29], on PKD1 serine
phosphorylation. CCK-JMV caused an increase in PKD S916
and S744/748 phosphorylation detectable above 10 nM and
reaching a maximum at 100 nM (Fig. 5). For both sites, the
maximal stimulation by CCK-JMV was one fifth of the
maximal stimulation by CCK (Fig. 5, Table 1). Co-stimulation
with CCK (1 nM) and CCK-JMVat variable concentrations led
to a dose-dependent inhibition of CCK-mediated PKD1 S916
and S744/748 phosphorylation by CCK-JMV. After co-
stimulation with CCK (1 nM) and maximal CCK-JMV
concentrations (10 μM), phosphorylation of both S916 and
S744/748PKD1 was comparable to phosphorylation stimulated
by 10 μM CCK-JMV alone (Fig. 5). Together, these data
demonstrate that 80% of the effect of CCK on PKD1
phosphorylation is mediated by activation of the low-affinity
CCKA receptor and that 20% is mediated by activation of the
high-affinity CCKA receptor state.
3.6. CCK-induced PKD1 phosphorylation is partly dependant
on PKC and strongly inhibited by depletion of intracellular
calcium
Binding of CCK to its receptor causes activation of PLC-β,
leading to an increase of intracellular calcium levels and
activation of PKC through diacylglycerol [26,30]. To assess the
respective roles of PKC and intracellular calcium signaling on
CCK-mediated PKD1 phosphorylation, we analyzed the effect
of GF109203X, an inhibitor of classical and novel PKC
isoforms [31], and thapsigargin, an agent that specifically
inhibits the endoplasmic reticulum ATPase, which depletes
Ca++ from intracellular compartments in a calcium-free medium
after 1 h of incubation [23]. Furthermore, we analyzed the effect
of TPA, an activator of classical and novel PKC isoforms, on
PKD1 phosphorylation. TPA (1 μM) stimulated PKD1 S916
and S744/748 phosphorylation to a comparable degree to
stimulation by 10 nM CCK (Fig. 6, top panel). TPA-induced
PKD1 phosphorylation was completely inhibited by pre-
incubation of pancreatic acini with GF109203X (Fig. 6, top
panel), demonstrating effective inhibition of classical/novel
PKC isoforms by GF109203X under our experimental condi-
tions. In contrast, CCK-induced PKD1 phosphorylation was
only partly inhibited by pre-incubation with GF109203X (Fig.
6, top panel). Specifically, CCK-stimulated pS916 PKD1
phosphorylation was inhibited by 62±7% by GF109203X,
which was significantly (p<0.026) less than the 87±2%
inhibition of pS744/748 PKD1 phosphorylation. Depletion of
intracellular calcium by thapsigargin caused a 96±2% and 87±
3% inhibition of CCK-induced PKD1 S916 and S744/748
phosphorylation, respectively (Fig. 6, top panel), but did not
have a significant effect on TPA-mediated PKD1 phosphoryla-
tion (Fig. 6, top panel). Both CCK- and TPA-mediated PKD1
phosphorylation were completely inhibited after pre-incubation
of pancreatic acini with GF109203X and thapsigargin in
combination (Fig. 6, top panel). An acute increase in
intracellular calcium by short-term incubation with thapsigargin
in calcium-containing media did not cause PKD1 phosphoryla-
tion but potentiated TPA-mediated PKD1 phosphorylation (Fig.
Fig. 4. Time course of CCK stimulation of PKD1 S916 and S744/748 phosphorylation in rat pancreatic acini. Rat pancreatic acini were treated with no additions or
with 10 nM CCK for the indicated periods of time and then lysed. Upper 2 panels: membranes were analyzed using anti-pS916 PKD1 Ab (panel 1). To verify loading
of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 2). Lower 2 panels: membranes were analyzed using anti-pS744/748
PKD Ab (panel 3). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 4). The bands were visualized
using chemiluminescence and quantification of phosphorylation was assessed using scanning densitometry. The upper part shows a representative experiment. The
values shown in the bottom part are the means±S.E. of 4 independent experiments and are expressed as fold increases over the pretreatment level (exp/control).
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shown). These results demonstrate that CCK-stimulated PKD1
phosphorylation is mediated by activation of both arms of the
phospholipase C-mediated cascade with participation of both
PKC-dependent and -independent pathways, however, the
contribution of these different pathways varies for the two
serine phosphorylation sites. Furthermore, these data suggest an
important role for intracellular calcium in CCK-mediated PKD1
activation.
3.7. PKD1 activation by CCK is partly dependent on
PLC-mediated PKC activation
CCK-induced PKC activation is mediated by PLC-β in
pancreatic acini [30]. To analyze the role of PLC in PKD1
activation by CCK, we studied the influence of the PLCinhibitor U-73122 on CCK-mediated PKD1 phosphorylation.
U-73122 caused an almost complete inhibition (88.3±3.9%) of
CCK-mediated PKD1 S744/748 and a partial inhibition (55.6±
5.5%) of S916 phosphorylation (Fig. 7, top panel).
Chronic treatment with phorbol ester for 24 h has been shown
to cause down-regulation of novel/classical PKC isoforms, but
not PKD [32]. In pancreatic acini, TPA (1 μM/24 h) caused
complete down-regulation of PKC-δ and PKC-ε and com-
pletely inhibited TPA and CCK-stimulated PKD1 S744/748
phosphorylation (Fig. 7, bottom panel). However, after 24 h
TPA treatment, CCK could still trigger an increase in PKD1
S916 phosphorylation, which corresponds to 19% of the
maximal increase without TPA pre-treatment. Together, these
findings suggest that approximately 80% of PKD1 activation
is mediated by a PLC-PKC dependent pathway but that 20%
is mediated by a PKC-independent pathway.
Table 1
Comparison of site-specific phosphorylation of PKD1 in rat pancreatic acini a
Variable PKD1 serine phosphorylation
pS916 pS744/748 p
Stimulation by pancreatic secretagogues b
Yes CCK, carbachol, bombesin CCK, carbachol, bombesin
No Secretin, VIP, endothelin Secretin, VIP, endothelin
Stimulation by pancreatic growth factors c
Yes – –
No Insulin, EGF, PDGF, VEGF, bFGF,
IGF1, TGFβ, HGF
Insulin, EGF, PDGF, VEGF,
bFGF, IGF1, TGFβ, HGF
Stimulation by post-receptor activators
Yes TPA TPA
No Ionophore, 8-Br-cAMP Ionophore, 8-Br-cAMP
t1/2 of CCK
d (s) 28.9±3.1 103±7.4 0.0031
tmax of CCK
d (s) 525±75 900±122 NS e
EC50 of CCK
f (nM) 0.14±0.02 0.19±0.05 NS
EC50 of CCK-JMV
f (nM) 1070±725 119±60 NS
Fold increase with CCK (100 nM)f 53.4±7.2 11.2±1.3 0.013
Fold increase with CCK-JMV (10 μM)f 4.4±0.9 2.5±0.4 NS
CCK stimulation with GF109203X (5 μM)
(% CCK alone)
38.0±3.2 13.0±0.8 0.026
CCK stimulation with Thapsigargin (1 μM)
(% CCK alone)
4.2±0.8 14.4±1.4 0.032
CCK stimulation with Go6976 (10 μM)
(% CCK alone)
57.5±20.0 86.9±17.3 NS
CCK stimulation with Go6983 (10 μM)
(% CCK alone)
51.5±9.1 17.6±2.1 0.011
a Results are calculated from the data shown in Figs. 2–8. For CCK stimulation after pre-incubation with GF109203X, thapsigargin, Go6976 and Go6983, results
are expressed as the percentages of the stimulation seen with CCK (10 nM) after pre-incubation in incubation buffer without any additions.
b Concentrations and incubation times are reported in Fig. 2.
c Concentrations and incubation times are reported in Fig. 2.
d Stimulation with 10 nM CCK as described in Fig. 4.
e NS: p value not significant (=0.05).
f Stimulation with CCK for 5 min as described in Fig. 5.
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atypical PKC isoforms on TPA- and CCK-induced PKD1
phosphorylation
Four PKC isoforms (α, δ, ε, ζ) have been reported to occur in
pancreatic acini [33–36]. To elucidate which PKC isoforms are
involved in CCK-mediated PKD1 phosphorylation, we used
Go6976, a selective inhibitor of classical PKC isoforms and
PKD1 [37], Go6983, a general PKC inhibitor [37] and PKC-ζ
pseudosubstrate, a specific cell-permeable inhibitor of PKC-ζ
[38]. TPA-mediated phosphorylation of the PKD1 auto-
phosphorylation site S916 was significantly inhibited by
classical PKC/PKD inhibitor Go6976 (Fig. 8, lane 8), demons-
trating that this inhibitor was effective in our experimental
system. However, TPA-mediated phosphorylation of the PKD1
trans-phosphorylation site S744/748, which does not require
PKD1 catalytic activity, was not significantly altered by
Go6976 (Fig. 8, lane 8), demonstrating that classical PKC
isoforms are not involved in TPA-mediated PKD1 phosphor-
ylation. Similarly, Go6976 had no significant effect on CCK-
mediated PKD1 S744/748 phosphorylation, demonstrating
classical PKC isoforms are not involved in CCK-mediated
S744/748 phosphorylation. The general PKC inhibitor Go6983
completely inhibited TPA-mediated phosphorylation of bothphospho-specific PKD1 sites studied (Fig. 8, lane 9). In
contrast, Go6983 only partly inhibited CCK-induced PKD1
S744/748 phosphorylation and had a weak effect on CCK-
mediated S916 phosphorylation (Fig. 8, right panel and lane 9).
These results remained unchanged when different agonist
concentrations and incubation times were used (i.e. CCK
100 nM for 5 min and TPA 1 μM for 10 min) (data not shown),
suggesting that these results are not explained simply by
different concentrations or incubation times of the agonists
used. PKC-ζ pseudosubstrate, which has been shown to inhibit
PKC-ζ kinase activity in rat pancreatic acini under experimental
conditions identical to those used in the present study [33], had
no significant effect on TPA- or CCK-induced PKD1 S916 or
S744/748 phosphorylation (Fig. 8). These data support the
conclusion that CCK-mediated PKD1 phosphorylation is partly
dependant on novel PKC isoforms.
3.9. Effect of isoform-specific PKC translocation inhibitors and
dominant-negative PKC isoforms on CCK-mediated PKD1
phosphorylation
To determine which novel PKC isoform(s) mediate(s) PKD1
phosphorylation, we used two independent approaches. First,
we analyzed the effect of isoform-specific PKC translocation
Fig. 5. Concentration-dependence of CCK and CCK-JMV stimulation of PKD1 serine 916 and serine 744/748 phosphorylation in rat pancreatic acini. Left: Rat
pancreatic acini were treated with no additions, with CCK or CCK-JMV at the indicated concentrations for 5 min and then lysed. Upper 2 panels: membranes were
analyzed using anti-pS916 PKD1 Ab (panel 1). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 2).
Lower 2 panels: membranes were analyzed using anti-pS744/748 PKD1 Ab (panel 3). To verify loading of equal amounts of protein, membranes were stripped and re-
blotted with anti-PKD1 Ab (panel 4). Right: Rat pancreatic acini were treated with no additions or with CCK or/and CCK-JMV at the indicated concentrations for
5 min and then lysed. Whole cell lysates were submitted to SDS-PAGE and transferred to nitrocellulose membranes. Upper 2 panels: membranes were analyzed using
anti-pS916 PKD1 Ab (panel 1). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 2). Lower 2 panels:
membranes were analyzed using anti-pS744/748 PKD1 Ab (panel 3). To verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-
PKD1 Ab (panel 4). The bands were visualized using chemiluminescence and quantification of phosphorylation was assessed using scanning densitometry. The upper
part shows a representative experiment. The values shown in the bottom part are the means±S.E. of 4 independent experiments and are expressed as percentages of
maximal increase caused by 100 nM CCK.
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S744/748 transphosphorylation site. While the PKC-δ translo-
cation inhibitor δV1-1 caused a strong inhibition of PKD1
phosphorylation, the PKC-ε translocation inhibitor εV1-2 had
no significant effect (Fig. 9). Second, using an adenoviral
vector, we expressed dominant negative PKC-δ and PKC-ε
isoforms as described previously [25]. These dominant
negative (DN) mutants encode the full-length protein, but
contain a single amino acid substitution in a critical ATP
binding residue, rendering the kinase inactive [39]. As reported
previously [25], infection with 109 pfu/mg of acinar protein
leads to expression of the protein of interest in 100% of cells
(Fig. 9, panel D). Infection with an empty adenoviral vector or
with Ad-5-DN PKC-ε had no effect on PKD1 phosphorylation,
but infection with Ad-5-DN PKC-δ strongly inhibited CCK-
mediated PKD1 phosphorylation (Fig. 9). These data furtherdemonstrate that PKC-δ is the main PKC isoform involved in
PKD1 activation.
3.10. CCK-stimulated PKD1 phosphorylation is not dependant
on Src, PI3K, MAPK or tyrosine phosphorylation
To further characterize possible signaling cascades con-
tributing to PKD1 phosphorylation in rat pancreatic acini, we
analyzed the effect on CCK-stimulated PKD1 phosphorylation
of the inhibition of several pathways reported to be important in
mediating PKD1 activation in other cellular systems with other
stimulants [4,5,40]. Inhibition of Src by PP2, PI3K by
wortmannin or LY294002, MAPK by PD98059 or U0126 and
inhibition of tyrosine phosphorylation by B44, a wide-spectrum
tyrosine kinase inhibitor [41] had no effect on CCK-mediated
S916 or S744/748 phosphorylation (Fig. 10). These inhibitors
Fig. 6. Top: effect of the PKC inhibitor GF109203X and/or depletion of intracellular calcium with thapsigargin on CCK- (left panel) and TPA- (right panel) stimulated
PKD1 S916 and S744/748 phosphorylation in rat pancreatic acini. Rat pancreatic acini were pretreated for with no additions, with GF109203X (5 μM) for 2 h or with
thapsigargin (1 μM) in a calcium-free medium (with EGTA 5 μM) for 1 h. Acini were then incubated with no additions (control), with 10 nM CCK for 10 min or with
1 μMTPA for 5 min and then lysed. Upper 3 panels: membranes were analyzed using anti-pS916 PKD1 Ab (panel 1) or anti-pS744/748 PKD1 Ab (panel 2). To verify
loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab (panel 3). Lower panel: for positive control for calcium-free
conditions, membranes were analyzed using anti-phospho PYK2 (Y402) Ab (panel 4). The bands were visualized using chemiluminescence and quantification of
phosphorylation was assessed using scanning densitometry. The upper part shows a representative experiment of 5 independent experiments. Bottom: effect of an acute
increase in intracellular calcium on PKD1 phosphorylation. Rat pancreatic acini were treated with TPA (10 nM) and/or Thapsigargin (1 μM) for 10 min and then lysed.
Membranes were analyzed using anti-pS916 PKD1 Ab (panel 1) or anti-pS744/748 PKD1 Ab (panel 2). To verify loading of equal amounts of protein, membranes
were stripped and re-blotted with anti-PKD1 Ab (panel 3). A representative blot of 3 independent experiments is shown.
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cascades in pancreatic acini [42–45]. To ensure that this lack of
effect was not due to a general non-responsiveness of our
pancreatic acinar preparation to these inhibitors, controls to
verify specific inhibition of a typical phosphorylation event
were included for each inhibitor (Fig. 10).
3.11. PKD1 translocates to the membrane after CCK
stimulation in rat pancreatic acini
PKD membrane translocation is reported to be a crucial
step in PKD activation in response to different stimuli in
numerous cellular models [5,12,13,46]. To analyze intracel-
lular distribution of total PKD in quiescent and stimulated
intact pancreatic acini, cells were submitted to immunocyto-
chemistry-immunofluorescence. In non-stimulated acini,
PKD1 was distributed diffusely in the cytoplasm, with only
minimal staining at the membrane (Fig. 11, panels B1–B2).
After stimulation with CCK (Fig. 11, panels C1–2, D1–2) or
TPA (Fig. 11, panels E1–2, F1–2), there was a rapid
translocation to the membrane, obvious at 5 min (Fig. 12,
panels C1–2, E1–2) and lasting at least 30 min (Fig. 11,
panels D1–2, F1–2). The membrane translocation of PKD1
after stimulation is confirmed by a co-localization with themembrane marker E-cadherin (Fig. 11, panels C2–F2). To
quantitate the PKD1 translocation response, subcellular
fractions of rat pancreatic acini were analyzed by Western
blotting (Fig. 12). In non-stimulated acini, 80±7% of total
PKD was found in the cytoplasmic fraction (Fig. 12, lanes 1,
6), confirming results of the immunocytochemistry. After
stimulation with TPA, there was a marked increase of total
PKD in the membrane fraction detectable at 1 min (data not
shown), obvious at 5 min (Fig. 12, lane 7) and lasting at least
30 min (Fig. 12, lane 9) whereas PKD completely disappeared
from the cytoplasmic fraction (Fig. 12, lanes 2, 4), indicating a
pronounced and durable translocation of PKD to the
membrane. Similarly, after CCK stimulation, total PKD
increased by 209±57% at 1 min (data not shown), 357±
105% at 5 min and 305±75% at 30 min in the membrane
fraction (Fig. 12, lanes 8, 10). A marked increase in PKD1
phosphorylated at S916 and S744/748 was detectable in the
membrane fraction after 1 (data not shown), 5 and 30 min
CCK and TPA stimulation (Fig. 12, lanes 7–10) and in the
cytoplasmic fraction after CCK stimulation only (Fig. 12,
lanes 2–5). To verify separation of cytosolic and membrane
fractions and equal loading of protein, lysates from subcellular
fractions were analyzed for E-Cadherin (located in cell
membranes) and Calpain (located in the cytosol). This analysis
Fig. 7. Top: effect of the inhibition of phospholipase C on CCK stimulated
PKD1 S916 and S744/748 phosphorylation in rat pancreatic acini. Rat
pancreatic acini were pretreated for 3 h with no addition, with the inactive
compound U-73343 (10 μM) or the active compound U-73122 (10 μM).
Subsequently, acini were incubated with no additions (control) or with 10 nM
CCK for 10 min and then lysed. Upper panel: membranes were analyzed using
anti-pS916 PKD1 Ab. Middle panel: membranes were analyzed using anti-
pS744/748 PKD1 Ab. Lower panel: to verify loading of equal amounts of
protein, membranes were stripped and re-blotted with anti-Tubulin Ab. The
bands were visualized using chemiluminescence and quantification of
phosphorylation was assessed using scanning densitometry. A representative
experiment of 3 independent experiments is shown. Bottom: effect of PKC
down-regulation by 24 h TPA incubation on CCK and TPA stimulated PKD1
S916 and S744/748 phosphorylation in rat pancreatic acini. Rat pancreatic acini
were cultured on collagen-coated dishes in Waymouth's Medium with 5% FCS
as described in Methods and pretreated with no addition or with 1 μM TPA for
24 h. Subsequently, acini were incubated with no additions (control), with
10 nM CCK for 10 min or with 1 μM TPA for 5 min and then lysed. Panel 1:
membranes were analyzed using anti-pS916 PKD1 Ab. Panel 2: membranes
were analyzed using anti-pS744/748 PKD1 Ab. Panel 3: membranes were
analyzed using anti-PKC-δ Ab. Panel 4: membranes were analyzed using anti-
PKC-ε Ab. Lower panel: to verify loading of equal amounts of protein,
membranes were stripped and re-blotted with an anti-Tubulin Ab. The bands
were visualized using chemiluminescence. A representative experiment of 3
independent experiments is shown.
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equal loading.
4. Discussion
Our results demonstrate that PKD1 is present in rat
pancreatic acini and is phosphorylated in response to GI
hormones/neurotransmitters that activate phospholipase C, but
not by GI hormones/neurotransmitters stimulating other
transduction cascades or by pancreatic growth factors. We
showed that CCK induced a 8.6-fold increase in PKD1
autophosphorylation and a 2.2-fold increase in phosphorylationof an exogenous substrate by PKD1, demonstrating PKD1
activation by CCK. These increases in PKD activity are
comparable to the 4- to 8- fold increase in autophosphorylation
and the 2.6–4 fold increase in syntide-2 phosphorylation
reported in the literature [7,20,47]. The lower increase in
activity of these kinase assays when compared to phosphoryla-
tion assays probably reflects different sensitivities of these
assays. As rat pancreatic acini express exclusively CCKA and
not CCKB receptors, our results for the first time show that
CCKA receptors can lead to PKD1 activation. Moreover,
because the extent of PKD1 S916 phosphorylation has been
shown to closely reflect the activation status of PKD1
[11,32,48], the presence of phosphorylated S916 PKD1 after
stimulation with CCK, carbachol or bombesin supports the
conclusion that PKD1 is activated by these stimuli in pancreatic
acini. Our results, showing lack of effect of endothelin or
growth factors in pancreatic acini, differ from studies in other,
mostly transformed and/or transfected cells which report
activation of PKD1 can also be mediated by endothelin [20]
or by various growth factors including PDGF [27] or by VEGF
[4,49]. These data suggest that not only may the cellular basis of
PKD1 activation by a given growth factor or GI hormone/
neurotransmitter vary from one tissue to another, it may also
vary from normal cells to transfected and/or neoplastic cells.
There are no studies that have compared in detail the kinetics
and stoichiometry of PKD1 S916 (autophosphorylation site)
and S744/748 (PKC transphosphorylation site) by a given
stimulus. In general, for the individual serine phosphorylation
sites, our kinetic and stoichiometric results agree with previous
studies [21,50], which show a rapid stimulation of PKD1
activation with a sustained effect lasting over 60 min and an
EC50 of most stimulants in the nanomolar range. However, we
found that CCK stimulation of the serine phosphorylation sites
S744/748 and S916 differed in kinetics and efficacy. Specifi-
cally, CCK caused a significantly faster onset of S916 phospho-
rylation by CCK (t1/2=28.9 vs. 103 s, p=0.0031, Table 1) with
a comparable tmax. This result is somewhat unexpected because
studies with PKD1 mutants have shown that S744/748
phosphorylation is required for PKC-mediated PKD1 activation
[51] and in a recent model of PKD1 activation by GPCRs, S744/
748 phosphorylation was proposed to be an essential phosphor-
ylation step leading to PKD1 activation and autophosphoryla-
tion of the S916 site of PKD1 [52]. However, evidence exists
from a study of BMP-2, which binds to a cell surface serine-
threonine kinase receptor, leading to PKD1 activation by sti-
mulating S916 serine phosphorylation without affecting S744/
748 phosphorylation [53]. While multiple explanations for the
more rapid serine phosphorylation of S744/748 by CCK could
be proposed, including different levels of amplification, an
important possibility is that PKC-dependent and -independent
pathways of PKD1 phosphorylation with different kinetics
could exist in rat pancreatic acini.
In pancreatic acini the CCKA-receptor has been shown to
exist in both a low-affinity and a high-affinity receptor state,
each of which can activate multiple, distinct downstream
signaling cascades [19,54–56]. Our data support the conclusion
that CCK-induced PKD1 activation and serine phosphorylation
Fig. 8. Effect of the inhibition of classical/novel/atypical PKC isoforms on TPA (left panel) and CCK (right panel) stimulated PKD1 S916 and S744/748
phosphorylation in rat pancreatic acini. Rat pancreatic acini were pretreated for with no addition, with GF109203X (5 μM), Go6976 (10 μM), Go6983 (10 μM) for 2 h
or with PKCζ pseudosubstrate inhibitor (10 μM) for 3 h. Subsequently, acini were incubated with no additions (control), with 10 nM CCK for 10 min or with 1 μM
TPA for 5 min and then lysed. Upper panel: membranes were analyzed using anti-pS916 PKD1 Ab. Middle panel: membranes were analyzed using anti-pS744/748
PKD1 Ab. Lower panel: to verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab. The bands were visualized using
chemiluminescence and quantification of phosphorylation was assessed using scanning densitometry. The upper part shows a representative experiment. The values
shown in the bottom part are the means±S.E. of 6 independent experiments and are expressed as percentages of maximal increase caused by 1 μMTPA or 10 nMCCK.
** and *** indicate p<0.01 and p<0.001 compared to stimulation with CCK or TPA alone.
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the low (80%) and the high affinity state (20%) of the CCKA-
receptor. This is relevant because activation of the high-affinity
CCKA receptor state by JMV does not lead to PLC or PKC
activation in pancreatic acini [57], suggesting the participation
of PLC/PKC-independent pathways of PKD1 activation in
these cells. Nevertheless, 80% of PKD1 activation in pancreatic
acini is mediated by the low affinity CCKA receptor, which is
coupled to PLC activation, and the important role of PLC is
illustrated by the pronounced inhibition of PKD1 S744/748
phosphorylation by the PLC inhibitor U-73122.
While the importance of PKC stimulation in mediating
PKD1 activation has received considerable attention [52], the
role of changes in intracellular calcium in mediating PKD1
activation is unclear because the few studies investigating the
role of calcium in PKD1 activation and serine phosphorylation
gave contradictory results. In pancreatic acini, activation of theCCKA-receptor leads to PLC activation, which in turn results in
the formation of diacylglycerol (DAG) and inositol 1,4,5
triphosphate (IP3) [26,57,58]. DAG binds and activates PKCs,
while IP3 causes an increase in intracellular calcium levels
[19,59]. Several lines of evidence in our study support the
conclusion that CCK stimulation of both arms of the PLC-
pathway, i.e. PKC activation and changes in cytosolic calcium,
mediate PKD1 serine phosphorylation and that both PKC-
dependent and PKC-independent signaling mechanisms are
important. First, we found a >80% suppression of CCK-
induced PKD1 serine phosphorylation at both the S744/748 and
the 916 site after inhibiting CCK-mediated changes in cytosolic
calcium using thapsigargin in a calcium-free medium. This
result was not due to a toxic effect of thapsigargin on pancreatic
acini because TPA-mediated PKD1 serine phosphorylation at
neither S744/748 nor the S916 site was altered. Second, the
general (classical, novel) PKC inhibitor GF109203X [31,38]
Fig. 9. CCK-induced PKD1 phosphorylation is mediated by PKC-δ. Top: rat pancreatic acini were pretreated for with no addition, with the PKC-δ translocation
inhibitor δV1-1 (10 μM) or the PKC-ε translocation inhibitor εV1-2 (10 μM) for 4 h. Subsequently, acini were incubated with no additions (control) or with 10 nM
CCK for 10 min. Upper panel: membranes were analyzed using anti-pS916 PKD1 Ab. Lower panel: to verify loading of equal amounts of protein, membranes were
stripped and re-blotted with anti-tubulin Ab. These results show a representative experiment of 3 independent experiments. Bottom: rat pancreatic acini were cultured
as described in Methods and infected with no addition (Pictures A, C), with an empty adenoviral vector or with adenovirus encoding GFP (Pictures B, D), DN-PKC-δ
or DN-PKC-ε. Pictures A/C show phase contrast microscopy and Pictures B/D show fluorescence microscopy after 24 h. After 24 h, acini for western blot experiments
were incubated with no additions (control) or with 10 nM CCK for 10 min and then lysed. Whole cell lysates were submitted to SDS-PAGE and transferred to
nitrocellulose membranes. Upper panel: membranes were analyzed using anti-pS744/748 PKD1 Ab. Second panel: membranes were analyzed using anti-PKC-δ Ab.
Third panel: membranes were analyzed using anti-PKC-εAb. Lower panel: to verify loading of equal amounts of protein, membranes were stripped and re-blotted with
anti-Tubulin Ab. The bands were visualized using chemiluminescence. These results show a representative experiment of 3 independent experiments.
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phosphorylation (Fig. 6). This lack of complete inhibition was
not due to incomplete PKC inhibition because GF109203X was
used at concentrations that completely inhibited S916 phos-
phorylation induced by the classical/novel PKC activator TPA.
Third, CCK caused PKD1 activation through stimulation of
both the high (20% of maximum) and low affinity (80% of
maximum) CCKA receptor states. However, only activation of
the low affinity CCKA receptor state is coupled to cascades
activating PKC in pancreatic acini [56–58], supporting the
conclusion that 20% of maximal PKD1 activation is mediated
by a PKC-independent mechanism. Fourth, after 24 h of TPA
incubation, there was a complete down-regulation of novel PKC
isoforms and, consequently, of PKD1 S744/748 transpho-
sphorylation. However, CCK could still cause an increase in
PKD1 S916 phosphorylation (20% of maximal increase),
suggesting again that 20% of PKD activation is mediated
independently of PKC. Our results, showing that both PKC-dependent and PKC-independent pathways are important in
mediating serine phosphorylation of PKD1 at S916 and S744/
748 sites, are in contrast to those of others showing complete or
almost complete inhibition of PKD1 activation by different
stimuli after pre-incubation with GF109203X in Swiss 3T3 cells
or rat-1 cells transfected with the rat CCKB receptor [21,22] and
in a number other cells [20,60–62], including rat parotid acinar
cells stimulated with carbachol [63]. Our results therefore
contrast with the conclusion of a number of other studies in
other tissues reporting that stimulation of PKD1 by GPCR
activation is exclusively PKC-mediated [21,22,60,63]. How-
ever, our finding of PKD1 activation mediated partly through
PKC-independent signaling cascades in rat pancreatic acini is
consistent with other studies of PKD1 activation in response to
the growth hormone BMP-2 in osteoblasts and mesenchymal
stem cells [53,64], the cytostatic agent Ara-C in myeloid
leukemia cells [65] or oxidative stress in HeLa cells [40].
Different mechanisms of PKC-independent PKD activation
Fig. 10. Inhibition of Src (A), PI3K (B), MAPK (C) or tyrosine phosphorylation (D) have no effect on CCK-stimulated PKD1 S916 and S744/748 phosphorylation in
rat pancreatic acinar cells. Rat pancreatic acini were pretreated for with no addition or with PP2 (10 μM) or PP3 (10 μM) (A), with LY294002 (100 μM) for 1 h or with
wortmannin (10 μM) for 30 min (B), with U0126 (20 μM) for 1 h or PD98059 for 30 min (C) and with B44 (300 μM) for 1 h. Subsequently, acini were incubated with
no additions (control), with 10 nM CCK for 10 min or with 1 μM TPA for 5 min or with 1 nM HGF for 10 min and then lysed. Whole cell lysates were submitted to
SDS-PAGE and transferred to nitrocellulose membranes. Upper panel: membranes were analyzed using anti-pS916 PKD1 Ab. Second panel: membranes were
analyzed using anti-pS744/748 PKD1 Ab. Third panel: to verify loading of equal amounts of protein, membranes were stripped and re-blotted with anti-PKD1 Ab.
Lower panel: to verify that the used inhibitors could influence cellular functions in our experimental model, membranes were analyzed with anti-pY416 Src (A, D),
anti-pS473 Akt (B) or anti-pMAPK (C) as positive controls. The bands were visualized using chemiluminescence and quantification of phosphorylation was assessed
using scanning densitometry. These results show a representative experiment of 3 others.
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cleavage by caspase-3 [65] or tyrosine phosphorylation of PKD
[40]. The present study does not provide further insight into theexact mechanism(s) involved, but our results for the first time
provide strong support for the conclusion that PKC-independent
pathways can be important in GPCR agonist-mediated activa-
Fig. 12. Ability of CCK and TPA to stimulate translocation of total PKD and phospho-PKD to the cell membranes in rat pancreatic acinar cells. Acini were incubated
with or without 1 μMTPA or 10 nM CCK for the time periods indicated. Samples were then processed as described in Methods to obtain subcellular fractions. Lysates
from these fractions were submitted to SDS-PAGE and transferred to nitrocellulose membranes. Upper 3 panels: membranes were analyzed using anti-PKD Ab, anti
pS916PKD1 Ab or anti pS744/748PKD1 Ab. Lower 2 panels: to assess the effectiveness of subcellular fractionation, the cytosol and membrane fractions were
analyzed using anti-E-Cadherin Ab, a marker for the membrane fraction or anti-Calpain Ab, a marker for the cytosol, fraction. The bands were visualized using
chemiluminescence and quantification of phosphorylation was assessed using scanning densitometry. The upper part shows a representative experiment. The lower
part shows mean values±S.E. of 8 independent experiments. * and ** indicate p<0.05 and p<0.001, respectively, compared to the control group.
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pathways found in different cells in response to various
stimuli suggest that not only the cell, but also the stimulus
used can have an effect on the possible PKD1 activation
pathways stimulated.
Previous studies have shown the presence of one classical
PKC isoform (PKC-α), two novel PKCs (PKC-δ, ε) and one
atypical PKC (PKC- ζ) in rat pancreatic acini [33–36]. A
number of our results support the conclusion that PKC-δ is theFig. 11. PKD immunofluorescense-cytochemistry in rat pancreatic acini with and w
(10 nM) or TPA (1 μM) for time periods indicated below. After stimulation cells we
slides by cytocentrifugation as described in Methods. Cells were then labeled using po
antibodies. Specific binding was detected using an Alexa Fluor555- and Fluor488-c
PKD and green staining represents E-cadherin. Nuclei were counterstained using DAP
Panels A1–2 show acini without the addition of the primary antibodies but with norm
with incubation buffer only. Panels C1–2 and E1–2 show cells treated for 5 min with
show cells treated for 30 min with 10 nM CCK (panel D1–2) or 1 μM TPA (panels F
experiments. Cells shown are representative of >90% of total cells present.important PKC isoform in mediating CCK-dependent PKD1
activation. First, GF109203X, which has been shown to be an
inhibitor of classical and novel PKC isoforms in pancreatic acini
and other cells [31,33,38] or the classical/novel PKC inhibitor
Go6983 [37] significantly inhibited CCK stimulated PKD1
S744/748 phosphorylation, suggesting the involvement of
either PKC-α, δ or ε in PKD1 phosphorylation in pancreatic
acini. Second, Go6976, an inhibitor of classical PKC isoforms
and PKD1 activity [37] had no significant effect on PKD1ithout CCK treatment. Pancreatic acini were incubated with no addition, CCK
re washed, fixed, permeabilized and transferred onto poly-L-lysine coated glass
lyclonal rabbit anti-PKD (Santa Cruz, C-20) and mouse anti E-cadherin primary
onjugated secondary antibodies so that red staining represents staining for total
I (blue). Fluorescent images were collected using a Leica CTR5000 microscope.
al isotype-matched serum as a negative control. Panels B1–2 show acini treated
10 nM CCK (panels C1–2) or 1 μM TPA (panel E1–2). Panels D1–2 and F1–2
1–2). Shown are results of a typical experiment representative of 6 independent
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conclusion that the conventional isoform, PKC-α, is not
involved in CCK-mediated PKD1 activation in pancreatic
acini. This conclusion is consistent with most [33,35,36], but
not all [34] recent studies which report CCKA receptor
activation does not activate PKC-α in pancreatic acini. Third,
PKC-ζ pseudosubstrate, a specific PKC-ζ inhibitor shown to
inhibit PKC-ζ kinase activity in rat pancreatic acini under the
same experimental conditions used in this study [33], had no
effect on CCK mediated PKD1 S744/748 phosphorylation,
illustrating that PKC-ζ is not involved in CCK-mediated PKD1
activation. Together, these data suggest that only the novel PKC
isoforms δ and/or ε can mediate PKD activation. Our studies
with isoform-specific PKC translocation inhibitors and domi-
nant negative PKC isoforms clearly show that PKC-δ mediates
CCK-induced PKD1 phosphorylation. This proposal is con-
sistent with previous studies that demonstrate CCK is a potent
activator of PKC-δ in pancreatic acini stimulating its tyrosine
phosphorylation, translocation to plasma and nuclear mem-
branes and its kinase activity [43,67]. This result is similar to
recent studies showing PKD1 activation in rat aortic smooth
muscle cells, HeLa cells, BON neuroendocrine cells and
intestinal epithelial cells is mediated by PKC-δ [48,68,69],
but differs from other reports which show PKD1 activation can
be mediated through PKC-α [49], PKC-ε [14,70], PKC-η
[70,71] or PKC-θ [72] in other cells with other stimulants.
These results suggest that PKD1 activation cannot only vary in
different cells with different stimulants in terms of the presence
or absence of PKC-independent activation, but also in the PKC
isoform mediating activation.
Various agents that activate PKD1 are reported to stimulate
its translocation to membranes in transfected and tumor cells
[5,12,13,46]. However, there are no studies in normal cells and
there is no data on the distribution of the serine-phosphorylated
PKD1 forms. In normal, unstimulated pancreatic acinar cells,
we found that PKD1 was almost entirely located in the
cytoplasm, which is similar to results reported in other cells.
Furthermore, we found that both TPA and CCK stimulated total
PKD translocation to membranes, however, there were several
differences. With TPA, all detectable PKD translocates rapidly
and durably to the membrane. This observation is in accordance
with a previous study [12] showing a durable membrane
translocation of a transfected GFP-PKD1 fusion protein after
phorbol ester stimulation in Cos-7 cells. After TPA stimulation,
PKD1 phosphorylated at S916 and S744/748 was detectable in
the membrane fraction only. In contrast to our results with TPA,
after CCK treatment, total PKD1 increased in membranes,
however the total amount of PKD1 translocated was sufficiently
small not to cause a change in the total PKD in the cytoplasm.
PKD1 forms phosphorylated at S916 and S744/748 were absent
in unstimulated cells and were found both in the membrane and
in the cytoplasm after CCK stimulation. These results support
the conclusion that after stimulation with TPA or CCK, PKD1
rapidly translocates to the plasma membrane, however, the
magnitude and duration of translocation is much greater with
TPA. While our results with CCK suggest that PKD1 serine
phosphorylation could be occurring either in the cytoplasm orplasma membrane, our results with TPA suggest the phosphor-
ylation is occurring in the membrane fraction, because no PKD1
was detected in the cytoplasm and the phosphorylated form of
PKD1 was detected only in the membrane fraction. Similar to
our study, transfected GFP-PKD1 translocated from the
cytoplasm to the membrane after bombesin stimulation in
fibroblasts and epithelial cells and then there was a rapid re-
distribution from the membrane to the cytoplasm, but in contrast
to our results, this re-distribution was complete within 10 min
after stimulation [13]. In another study, transfected GFP-PKD1
translocated from the cytoplasm to the membrane in transfected
ventricular fibroblasts and remained active in the membrane for
over 90 min [46]. At present it is unknown whether the marked
differences in the redistribution of PKD1 after stimulation with
various agents in different cell systems are due to the fact that we
are assessing a normal cell system, whereas others are analyzing
transfected cells or whether there is a difference in the
translocation of PKD1 with different stimulants in different
cells.
With various stimulants in other cells, PKD1 activation is
reported to be affected by Src kinases [14,68,73], PI3K [4] and
tyrosine phosphorylation of various cellular proteins [5,6]. We
found that CCK-mediated PKD1 activation is not dependent on
Src, PI3K, MAPK, activation or stimulation of tyrosine
phosphorylation. These results suggest that the importance of
Src kinases, PI3K and tyrosine phosphorylation of various
cellular proteins in PKD1 activation differs with different
stimuli in various cells.
In conclusion, we report for the first time that PKD1 is
expressed in rat pancreatic acini and activated by GI hormones/
neurotransmitters leading to activation of phospholipase C, but
not by GI hormones with other cellular mechanisms or by
pancreatic growth factors. CCK-induced serine phosphorylation
at both S744/748 and S916 sites was mediated by activation of
both the high affinity (20%) and low affinity (80%) CCKA
receptor state. In contrast to PKD1 activation in most other cells
studied, CCK-induced PKD1 activation was only partially
mediated by PLC/PKC in rat pancreatic acini and the principal
PKC isoform involved is PKC-δ. Our results show that CCK-
mediated PKD1 activation is highly dependent on changes in
intracellular calcium but is not mediated by Src, PI3K, MAPK
or tyrosine phosphorylation as reported for a number of other
stimulants in other cell systems. Upon stimulation by CCK,
PKD1 translocates to the membrane and marked increases of
phospho-S916 and phospho-S744/748 occurred both in the
membrane and, to a lesser degree, in the cytoplasm. However
with TPA, total translocation to the membrane occurs and
phosphorylated PKD1 forms are only present in the membrane,
suggesting phosphorylation is occurring at the membrane. In
agreement with some studies using transfected cell systems, but
not others, our results show that the majority of activated PKD1
persists at the membrane after activation, whereas a fraction is
redistributed to the cytoplasm. Our results demonstrate a
number of novel aspects of PKD1 activation in normal
pancreatic acinar cells by GI hormones/neurotransmitters not
generally reported in studies of tumor cells or transfected cells.
Particularly important are the demonstration of the importance
499M.J. Berna et al. / Biochimica et Biophysica Acta 1773 (2007) 483–501of PKC-independent stimulation, the demonstration of the
importance of calcium-mediated cellular processes for activa-
tion of PKD1 and the lack of involvement of a number of other
cellular signaling cascades reported important with other
stimuli. These results emphasize the importance of studying
the effects of stimulants of PKD1 in normal cell systems.
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